This Viewpoint discusses the challenges of testing vaccines for pregnant women and the need for quick deployment during outbreaks of infectious disease.
This evidence review summarizes published reports of measles and pertussis outbreaks to characterize associations with vaccine delay, vaccine refusal, and waning immunity.
This Viewpoint discusses vaccine costs and policy and explains the importance of balancing these factors to provide optimal care while restricting spending on costly interventions with limited benefit.
This cohort study of women given Tdap vaccine during pregnancy evaluates associations between time since prior tetanus-containing vaccinations and acute adverse events in mothers and adverse birth outcomes.
This Viewpoint discusses how a recent measles outbreak may lead to tightening of US school immunization laws and describes the recent passage of such a law in California as an example other states might follow.
This randomized trial compares the immunogenicity and safety of avian influenza A(H7N9) vaccines that differ by adjuvant type and dosing schedule.
This Viewpoint proposes that development of an infant human immunodeficiency virus (HIV) type 1 vaccine is equally important as adult HIV-1 vaccine development to reduce maternal-child HIV transmission.
This report summarizes the experience of 1 patient with needlestick exposure to the Ebola virus and postexposure vaccination with VSVΔG-ZEBOV.
This Viewpoint discusses whether parental objections to mandatory childhood vaccinations justify decisions that place the community at risk.
This JAMA Clinical Guidelines Synopsis article evaluates the most recent Advisory Committee for Immunization Practices guideline on use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged 65 years or older.
This Viewpoint discusses types of exemptions from required vaccines and recent legislation to control numbers of nonmedical vaccine exemptions.
This cohort study of all Danish and Swedish girls and women aged 10 years to 44 years reports that quadrivalent human papillomavirus vaccination was not associated with development of multiple sclerosis or other demyelinating diseases.